The VLP-based poliovirus vaccine is a safe, effective alternative to traditional vaccines, showing strong neutralizing antibody production in trials. It offers a path to safer manufacturing by eliminating the need for live virus cultivation.
A phase 1 trial of a VLP-based poliovirus vaccine shows it is safe and generates robust immune responses comparable to conventional vaccines.
A VLP or virus-like particle vaccine uses proteins that mimic the structure of a virus to trigger an immune response without containing any viral genetic material. Because they lack DNA or RNA, they cannot replicate or cause disease, making them a safer alternative to live-virus vaccines.
The VLP vaccine performs comparably to the traditional inactivated poliovirus vaccine (IPV) in generating neutralizing antibodies. In phase 1 trials, the VLP vaccine achieved high geometric mean titers for serotypes 1 and 2, demonstrating it is highly immunogenic and capable of providing protective immunity.
No serious adverse events were reported in the phase 1 trial. The frequency of mild, solicited adverse events was similar between the VLP vaccine groups and the control group receiving the conventional IPV, suggesting the vaccine is well-tolerated.
The primary advantage is the elimination of live-virus manufacturing requirements. Traditional vaccines require large-scale cultivation of live poliovirus, which poses a risk of environmental release. VLP vaccines are safer to produce because they do not contain infectious material.